Growth factors and
growth factor receptors are involved in
tumor progression. The
fibroblast growth factor receptor 2 gene encodes distinct
isoforms. The
isoforms which bind KGF (
keratinocyte growth factor or FGF-7) are called KGF-R or
FGFR2b. KGF-R is expressed in different epithelia and is involved in the control of epithelial-mesenchymal interactions. Expression of KGF-R
mRNA was examined in normal human bladder and
transitional cell carcinoma of the bladder (TCC) by semi-quantitative RT-PCR using
TFIID and GAPDH as internal standards. In normal bladder, the KGF-R
mRNA was detected in the urothelium but not in the underlying stroma. In TCCs, the level of KGF-R
mRNA was generally either normal or low. Eighteen out of 54 TCCs had a KGF-R
mRNA level below 30% of that found in normal urothelium. This decrease in KGF-R
mRNA was not accompanied by an increase in BEK (
FGFR2c)
mRNA, the other major splice variant of the
fibroblast growth factor receptor 2 gene. Expression of the KGF-R was also monitored by immunohistochemistry using a functional KGF-
immunoglobulin chimera. The receptor was uniformly expressed throughout the normal urothelium except for the umbrella cells. Immunoreactivity for KGF-R was found to be negative in
tumors with low levels of KGF-R
mRNA, while the peritumoral normal urothelium was positive. Among patients with muscle invasive
tumors, those exhibiting a low level of KGF-R
mRNA had a significantly higher proportion of
cancer deaths. Our results suggest that decreased expression of KGF-R can be considered as a marker of
tumor progression in muscle invasive TCCs.